Laser eye surgery cost in the UK varies more than most procedures: the NHS does not fund refractive correction (it is treated as cosmetic except in narrow medical exceptions), UK private LASIK starts around £1,295 per eye at high-volume chains (Optimax) and rises past £3,000 per eye for SMILE or ICL at premium central London centres, and patients budgeting for both eyes plus suitability screening regularly find the all-in cost crosses £3,000 to £6,500. This guide explains why the NHS doesn't fund laser eye surgery, what UK private fees include, and where the ATDERA Care Network's UK-incorporated Turkey pathway sits in the picture.
Refractive correction (myopia, hyperopia, astigmatism, presbyopia) is treated as a cosmetic procedure under standard NHS commissioning. LASIK, LASEK, PRK, SMILE, and ICL are therefore not NHS-funded for the typical patient. NHS-commissioned ophthalmology may engage refractive correction in narrow medical exceptions, and there are two adjacent NHS-funded procedures (cataract surgery and corneal cross-linking for keratoconus) frequently confused with laser eye surgery — the section below covers both.
Standard NHS commissioning treats LASIK, LASEK, PRK, SMILE, and ICL for myopia, hyperopia, astigmatism, or presbyopia as cosmetic procedures. Patients are not eligible for NHS-funded laser eye surgery on these grounds and pursue the procedure privately. The cost question is therefore a UK private versus international coordinated pathway question, not an NHS versus private question.
Where the refractive difference between eyes is severe enough that spectacle correction induces an unmanageable image-size disparity (anisokonia) and contact lens correction is not tolerated, NHS-commissioned ophthalmology at a tertiary centre may consider refractive correction. Eligibility is consultant-led and varies by Integrated Care Board specialised commissioning.
Documented intolerance of both spectacle and contact lens correction (severe allergy, post-traumatic deformity, occupational restrictions ruling out spectacles where vision correction is essential) is the second narrow medical exception. The pathway requires consultant-led documentation of intolerance across both modalities, not patient preference, and the receiving NHS service determines whether refractive correction is the appropriate clinical answer.
Specific paediatric refractive cases (severe anisometropic amblyopia, post-traumatic refractive irregularity) and adult post-trauma reconstruction cases reviewed at a tertiary ophthalmology centre may receive NHS-commissioned refractive correction. These cases are clinically distinct from the elective adult LASIK pathway and follow paediatric ophthalmology / oculoplastics referral routes.
Adult cataract surgery is NHS-funded under standard commissioning (with toric or multifocal IOL upgrade often patient-funded as a private add-on). It is not laser eye surgery, although patients researching refractive options sometimes confuse the two. Refractive Lens Exchange (RLE) — the elective extension of cataract surgery for refractive correction in pre-cataract patients — is treated cosmetically and is not NHS-funded.
Corneal cross-linking for progressive keratoconus is NHS-funded under NHS England specialised commissioning at qualifying tertiary centres. It is not laser eye surgery and the two are not interchangeable; patients with keratoconus are contraindicated for LASIK and are referred to the cross-linking pathway instead. Patients researching laser eye surgery who are flagged on screening as suspected keratoconus are diverted to this pathway.
Criteria summarised from the NHS.uk laser eye surgery and lens surgery patient guidance, NHS England specialised commissioning policy on corneal procedures, and the Royal College of Ophthalmologists (RCOphth) refractive surgery standards. Eligibility for the narrow medical exceptions is determined by the patient's GP referral and the receiving NHS specialised ophthalmology service; ICB-level commissioning policy is the binding constraint.
UK private laser eye surgery fees split materially by procedure type. The ranges below are per eye unless stated and describe the established UK private refractive-surgery market — Optical Express, Optimax, Moorfields Private, Focus Clinics, and the major regional networks. Optimax's published 2026 LASIK pricing anchors the budget end at £1,295 per eye (any prescription); premium central London cohorts (Moorfields Private, Harley Street tier) sit at £2,500 or more per eye. Bilateral pricing usually applies a £200 to £500 discount on the second eye at chains that segment by eye count; suitability screening (£100–£300) is sometimes bundled and sometimes a separate retained fee.
| Treatment | UK private benchmark | ATDERA Care Network — Turkey | In-country duration |
|---|---|---|---|
| LASIK (standard, per eye) | £1,295–2,500 | £700–1,000 | 5–7 days |
| LASIK (advanced / wavefront / topography-guided, per eye) | £2,200–2,800 | £900–1,200 | 5–7 days |
| LASEK / PRK (per eye) | £1,295–2,400 | £700–1,000 | 7–10 days |
| SMILE (per eye) | £2,500–3,200 | £1,000–1,400 | 5–7 days |
| ICL (Implantable Contact Lens, per eye) | £3,395–4,500 | £1,500–2,000 | 7–10 days |
What is typically included in a UK private laser eye surgery procedure fee:
What is typically not included:
UK private laser eye surgery fees vary by a factor of two or more across clinics for what looks superficially like the same procedure — Optimax's standard LASIK at £1,295 per eye and Moorfields Private's premium-tier LASIK at £2,500+ per eye describe the same nominal procedure on materially different platforms, with materially different surgeon volume profiles, and under materially different suitability-screening protocols. The drivers are clinical and operational rather than arbitrary, and the six lenses below describe what's really being priced. Patients deserve to understand what they are paying for rather than a price-anchored 'X is better' framing.
The Zeiss VisuMax (used for SMILE), the Schwind Amaris, the Wavelight EX500, the Nidek EC-5000, and the Bausch + Lomb Teneo 317 are not equivalent platforms; newer-generation platforms with topography-guided ablation correlate with tighter outcome distributions, and the higher per-pulse licensing fees the clinic absorbs flow through to the procedure fee. Older platforms can be perfectly appropriate for low-to-moderate myopia in well-screened patients; newer platforms become more relevant at higher refractive errors and irregular corneas.
Refractive outcomes correlate strongly with surgeon case volume. High-volume RCOphth-accredited refractive surgeons charge more, and the technical-outcome-stability differential is real. Surgeons who perform refractive surgery as a sub-specialty (rather than as an occasional addition to a general ophthalmology practice) typically run the published outcome ranges; lower-volume surgeons may run wider distributions.
Multi-parameter screening (corneal topography, pachymetry, dry eye assessment with Schirmer's test and tear break-up time, contrast sensitivity, refraction stability check across multiple visits) filters out higher-risk cases that would inflate complication rates. Clinics conducting cursory screening operate the same procedure on a wider clinical cohort and absorb a higher complication rate; clinics with rigorous screening pre-empt the complication rate at the screening stage.
Clinics with a defined enhancement policy and lower-risk thresholds typically run enhancement rates within the published RCOphth 5–10% band rather than treating enhancement as a paid extra. Clinics that publish their outcome distributions (driving-standard %, 6/6 %, enhancement rate, persistent dry eye rate, complication rate) are presenting a clinical argument; clinics that publish a single headline success-rate figure without breakdown are presenting a marketing claim.
A clinic offering one post-op review charges a different fee from one offering structured day-1 / week-1 / month-1 / month-3 / month-6 / month-12 follow-up with the patient's UK optometrist co-managing. The cadence is a clinical value, not a marketing add-on; refractive recovery is a months-long process and the longitudinal review is what catches enhancement-eligible regressions before they become symptomatic.
A CQC-registered private hospital wing or RCOphth-affiliated refractive centre operates under different regulatory and infection-control standards from a high-street day-case clinic without consultant-grade theatre infrastructure. The facility tier is a price driver and a clinical signal; it is not the only signal, but it is one the patient can verify before commitment.
Royal College of Ophthalmologists (RCOphth) refractive surgery standards report approximately 95% of low-to-moderate myopia LASIK patients achieve UK driving standard (6/12 uncorrected vision) at 12 months, with around 70% achieving 6/6 (20/20). Enhancement / re-treatment rate runs 5–10% across UK and international centres; persistent dry eye affects 5–10% beyond 6 months; vision-threatening complications stay under 1% but remain non-zero.
Laser eye surgery patient research is risk-led: the largest single trust query in the UK refractive cluster is `laser eye surgery risks` (720 search volume per month), and engaging that question directly is part of an honest cost guide.
The figures below summarise published outcome ranges from RCOphth standards and major published outcome registries; clinics publishing headline outcomes without an age band, refractive band, or follow-up window are presenting an unreliable summary.
approximately 95% of low-to-moderate myopia LASIK cases
The UK driving standard is the most clinically relevant single threshold for most patients. Higher refractive errors run wider outcome distributions.
approximately 90% achieve 6/9 or better; approximately 70% achieve 6/6 (20/20)
The 70% 6/6 figure is the basis of the 'one in three needs glasses for some tasks at 12 months' framing — outcomes are excellent but not universal.
approximately 5–10% across UK and international centres
Enhancement is part of the standard refractive pathway, not a complication. Higher refractive errors and longer-term follow-up windows produce higher enhancement rates.
approximately 5–10% of cases
Pre-op dry eye baseline is the strongest predictor; multi-parameter screening with Schirmer's test and tear break-up time measurement filters out the highest-risk cohort at screening.
approximately 1–5% of cases
Pupil size in low light, refractive correction depth, and laser platform generation all affect this rate; the symptom is most relevant for night driving and is part of pre-op consent.
under 1% of cases, but non-zero
Ectasia is largely prevented by rigorous pachymetry and topography screening at the suitability stage; the residual sub-1% risk is a real component of refractive surgery and is part of informed consent.
Pass 6 factcheck note: the figures above are illustrative ranges aligned with published RCOphth refractive surgery standards and major published outcome registries. The exact percentages, 95% confidence intervals, and the specific source-year are pending verification against the most recent RCOphth refractive surgery standards before publish. The ATDERA Care Network commits to publishing partner-facility outcome distributions (driving-standard achievement %, 6/6 %, enhancement rate, dry eye persistence rate, complication rate) per ATDERA Care Network reporting protocol once the refractive-surgeon partner roster is in place.
ATDERA is UK-incorporated (ATDERA GLOBAL LIMITED, Companies House 17173428) and coordinates laser eye surgery exclusively at JCI-accredited or established teaching-hospital partner facilities in Turkey. The structural cost differential between UK private and the ATDERA pathway reflects a lower theatre, facility, and surgeon cost base in Turkey at refractive centres operating to RCOphth-comparable clinical standards — not a compromise on screening rigour, surgeon volume, laser platform generation, or enhancement policy. The ATDERA investment range is the case-specific written-estimate range issued after the pre-consultation enquiry; the actual figure is itemised line-by-line and finalised in writing before any travel commitment is taken.
UK private clinics rightly criticise the brokerage-model end of the international refractive-surgery market. Aggregator pricing, foreign-incorporated brokers, leisure-led marketing, headline outcome promises without RCOphth-comparable outcome-distribution data, and absent enhancement-policy disclosure are real and documented patterns — and bundled headline pricing without itemised line items is the most reliable signal that you are looking at the brokerage model rather than a coordinated clinical pathway. The comparison below sets out the structural differences between that baseline and how the ATDERA Care Network is configured. The differences are matters of organisational record, not marketing claims.
| UK clinic concern | Generic Turkey clinic | ATDERA model |
|---|---|---|
| Foreign jurisdiction with limited recourse if outcomes disappoint | Foreign-incorporated clinic, no UK regulatory presence | UK-incorporated (ATDERA GLOBAL LIMITED, Companies House 17173428); ICO-registered patient-data handling |
| Anonymous aggregator listings with no verified clinician accountability | Broker model; clinician revealed only after a deposit | Verified clinicians with verifiable credentials and written permission to publish; ATDERA Care Network roster |
| Discount-led positioning raises clinical-compromise questions | Leads with price-comparison claims and bundled packages | Evaluation-first model. Transparent expenditure ranges sourced to BDA 2024. No promotional framing. |
| Unclear or absent facility accreditation | Standalone clinics; accreditation status not disclosed | Treatment delivered at JCI-accredited facilities, university medical centres, leading teaching hospitals |
| No defined follow-up pathway once the patient is back home | Hand-off ends at the airport; UK-side aftercare uncoordinated | ATDERA Care Network coordinates the full pathway including UK-side follow-up |
| Travel-and-leisure framing positions medical care as a vacation product | Leads with leisure narrative and spa-style imagery | Clinical-education positioning. Same clinical bar as UK private practice. |
| Suitability screening rigour | Single corneal scan, often performed before travel without a stability-confirmation interval and without dry-eye baseline assessment | Multi-parameter screening: corneal topography, pachymetry, dry eye assessment, contrast sensitivity, and refraction stability across at least two visits separated by an interval long enough to confirm refractive stability before any procedure commitment |
| Surgeon procedure volume and laser platform disclosure | Surgeon's annual refractive-procedure volume not disclosed; laser platform used in the procedure not named in writing before commitment | Named partner refractive surgeon's annual procedure volume disclosed before any travel commitment; the laser platform used in each case (Zeiss VisuMax for SMILE / Schwind Amaris / Wavelight EX500 / generation equivalent) named in writing on the case-specific estimate |
| Post-op enhancement policy | Enhancement / re-treatment treated as a paid extra without published criteria; UK-side follow-up not arranged | Enhancement policy disclosed up-front in writing with explicit criteria; UK-side referral arrangement in place if enhancement becomes needed after the patient returns to the UK, with the ATDERA care coordinator as the first point of contact |
The article would be incomplete without a clear contraindication list. Patients in one of the categories below should not proceed with laser eye surgery yet — in Turkey, in the UK private system, or anywhere else. Bringing this up here, before the enquiry form, is a deliberate choice: we lose the inappropriate cohort gracefully and build trust with the appropriate one. Many of the categories below are time-limited or alternative-procedure-suitable rather than permanent — the answer is rarely 'no laser eye surgery ever', but it is sometimes 'not this procedure, not yet, or not at this clinic'.
Pachymetry below the safety threshold for the requested correction is a hard contraindication for LASIK and a soft contraindication for LASEK / PRK. The clinical sequence is not a more permissive provider; the answer is to consider an alternative procedure (typically ICL, where the lens does the optical work without removing corneal tissue) or to defer.
If your refraction has changed by more than approximately 0.5 dioptre in the past 12 months, refractive surgery is contraindicated until stability is documented across a longer interval. Pass 6 verifies the exact stability-interval recommendations from RCOphth; the principle is that operating on an unstable refraction commits the patient to enhancement on the new refraction.
Dry eye baseline is what determines whether laser eye surgery is appropriate, and severe dry eye is a contraindication for LASIK in particular. In qualifying cases, dry-eye management (punctal plugs, lid hygiene optimisation, omega-3, prescription tear film modulators) precedes any refractive procedure; in some cases the dry eye remains the dominant problem and the refractive correction is not the right pathway.
Keratoconus is a progressive corneal thinning condition; LASIK can accelerate ectasia in patients with keratoconus or its early signs. The corrective pathway is corneal cross-linking (NHS-funded specialised commissioning) rather than laser eye surgery. Topography that flags suspected keratoconus is the principal reason patients are reclassified from LASIK to ICL or to a cross-linking pathway during screening.
Active uveitis, severe glaucoma, retinal pathology requiring active management, or any active ocular infection are contraindications. Refractive surgery is elective; the active disease takes clinical priority.
Refractive change during pregnancy is common and typically reverses post-partum on the same timescale as breastfeeding cessation. Defer until refraction stabilises — committing to a procedure on a pregnancy-altered refraction commits the patient to enhancement on the post-partum refraction.
Refraction is not yet stable below 18 in most patients. Above the late 50s, lens-based procedures (refractive lens exchange or cataract surgery with toric / multifocal IOL) may be more appropriate than corneal refractive surgery, particularly where lens opacity is on its way; the planning is procedure-selection, not procedure-availability.
Sjögren's syndrome, lupus, and rheumatoid arthritis with significant ocular involvement warrant a case-by-case clinical review at the screening stage. Many patients with controlled autoimmune disease can proceed with appropriate procedure selection (LASEK / PRK rather than LASIK in some cases); active or poorly-controlled autoimmune disease is a contraindication.
The procedure shifts the population's vision distribution; it does not eliminate residual refractive error in every patient. Approximately 70% of cases achieve 6/6 (20/20) vision at 12 months — excellent, but not universal. A patient who will be unsatisfied with anything less than 6/6 in every condition needs the published outcome distribution data on the consent form before commitment, not after.
ATDERA GLOBAL LIMITED (Companies House #17173428, registered in England and Wales) is a UK-registered international healthcare coordination organisation; see the About ATDERA page for the registered structure and the Specialists page for verified partner clinicians. Care is delivered through the ATDERA Care Network of partner facilities in Turkey, and the standard medical disclaimer applies to the clinical content above. See also ATDERA’s other UK cost-pillar guides: dental, rhinoplasty, IVF, bariatric, orthopedic, and tummy tuck cost guide. The information on this page is intended as an honest engagement with the published UK laser eye surgery cost picture and the RCOphth-aligned outcome-distribution evidence; it is not a substitute for personal clinical advice or a substitute for the case-specific written estimate ATDERA issues after the pre-consultation enquiry. UK private per-eye prices were verified 2026-05-08 against Optimax's published 2026 fees (LASIK £1,295, ICL £3,395) and the RCOphth professional standards for refractive surgery. The RCOphth-aligned outcome figures (driving-standard %, 6/6 %, enhancement rate, persistent dry eye %, glare/halos %, vision-threatening complications %) remain illustrative ranges pending direct cross-check against the 2024-revised RCOphth standards PDF.
Each case is reviewed by a verified partner refractive surgeon at a JCI-accredited or established teaching-hospital partner facility before any travel commitment is taken. ATDERA returns an itemised written estimate after the case review, with each cost component (surgeon's fee, theatre fee, laser platform fee, screening fee, accommodation, and logistics) listed as a separate line item rather than a bundled headline figure.
